Refine Search
(0)
(5)
(24)
(65)

Ophthalmology

GlobalData provides unique and market-leading data and insights into the ophthalmology market. Browse or search our Report Store for the latest comprehensive reports, market data, analysis and survey findings alongside industry information on key companies, markets and financial deals.

PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022

  • $10,995
  • May 2013
Add to Basket Quick View Add to Saved List

The Dry Eye Syndrome (DES) pipeline is strong, with 49 molecules in various phases of development. More notably, the late-stage pipeline has three products with novel mechanisms of action to treat the inflammation associated with the disease. T...

PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024

  • $10,995
  • November 2015
Add to Basket Quick View Add to Saved List

DES, also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which can potentially damage the ocul...

PharmaPoint: Macular Edema and Macular Degeneration - Global Drug Forecast and Market Analysis to 2023

  • $10,995
  • October 2014
Add to Basket Quick View Add to Saved List

Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or b...

Pharmapoint: Glaucoma - Global Drug Forecast and Market Analysis to 2023

  • $10,995
  • May 2015
Add to Basket Quick View Add to Saved List

Glaucoma is a leading cause of preventable blindness globally. This chronic progressive optic neuropathy causes irreversible vision loss through damage to the optic nerve. There are currently no treatments that can directly prevent this damage,...

Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2026

  • $10,995
  • February 2018
Add to Basket Quick View Add to Saved List

There are two clinical forms of age-related macular degeneration (AMD): dry and wet. Currently there are therapies available only for wet AMD. Drugs in late stages of development target the wet AMD segment and the late stage or atrophic form of...

PharmaPoint: Glaucoma – Global Drug Forecast and Market Analysis to 2026

  • $10,995
  • December 2017
Add to Basket Quick View Add to Saved List

Glaucoma is the leading cause of irreversible vision loss, worldwide. The term glaucoma includes many different diseases, which are associated with differing risk factors, symptoms, treatment, and prognosis. All forms of glaucoma are characteri...

PharmaPoint: Age-Related Macular Degeneration - Global Drug Forecast and Market Analysis to 2026

  • $10,995
  • December 2017
Add to Basket Quick View Add to Saved List

There are two clinical forms of age-related macular degeneration (AMD): dry and wet. Currently there are therapies available only for wet AMD. Drugs in late stages of development target the wet AMD segment and the late stage or atrophic form of...

OpportunityAnalyzer: Uveitis Opportunity Analysis and Forecasts to 2026

  • $10,995
  • November 2017
Add to Basket Quick View Add to Saved List

Uveitis is an inflammatory condition of the eye affecting mainly the uvea. It encompasses a heterogeneous collection of disorders characterized by ocular inflammation. Currently, there is only a limited number of approved drugs for the treatmen...

PharmaPoint: Macular Edema – Global Drug Forecast and Market Analysis to 2026

  • $10,995
  • November 2017
Add to Basket Quick View Add to Saved List

ME is a condition characterized by the thickening and swelling (edema) of the macula, which is the area of the retina that is responsible for central vision. The occurrence of ME is highly frequent in diabetics and usually manifests itself as D...

Dry Eye Syndrome: Global Drug Forecast and Market Analysis to 2026

  • $10,995
  • June 2018
Add to Basket Quick View Add to Saved List

Dry Eye Syndrome (DES) is a multifactorial disease of the tears and ocular surface that causes ocular discomfort, visual disturbances, and tear film instability, which can potentially damage the ocular surface. With a rapidly accelerating world...

OpportunityAnalyzer: Uveitis – Opportunity Analysis and Forecasts to 2017

  • $7,995
  • December 2013
Add to Basket Quick View Add to Saved List

Uveitis is an expanding market currently dominated by corticosteroid treatment options as well as off-label immunosuppressive and biologic drugs. Since the conventional corticosteroid treatment is only effective in 50-60% of patients a signific...

OpportunityAnalyzer: Allergic Conjunctivitis – Opportunity Analysis and Forecasts to 2018

  • $7,995
  • September 2014
Add to Basket Quick View Add to Saved List

The allergic conjunctivitis market has remained relatively static over the last few years, due to a limited number of new products. It is currently dominated by dual-acting products and corticosteroid therapies, which form the core treatment op...

Macular Edema and Macular Degeneration – 5EU Drug Forecast and Market Analysis to 2023

  • $6,995
  • October 2014
Add to Basket Quick View Add to Saved List

Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or b...

Dry Eye Syndrome – 5EU Drug Forecast and Market Analysis to 2024

  • $6,995
  • November 2015
Add to Basket Quick View Add to Saved List

DES, also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which can potentially damage the ocul...

Glaucoma – 5EU Drug Forecast and Market Analysis to 2023

  • $6,995
  • May 2015
Add to Basket Quick View Add to Saved List

Glaucoma is a leading cause of preventable blindness globally. This chronic progressive optic neuropathy causes irreversible vision loss through damage to the optic nerve. There are currently no treatments that can directly prevent this damage,...

Join our mailing list
Find out first about the latest reports and offers.